PREECLAMPSIA BEYOND PREGNANCY: LONG-TERM CONSEQUENCES FOR MOTHER AND CHILD

Yusupova Gavxaroy Baxtiyajanovna
Kokanda University Andijan branch in Uzbekistan.

https://doi.org/10.5281/zenodo.17999444

Abstract. *Preeclampsia is a complex hypertensive disorder of pregnancy with systemic manifestations that extend far beyond delivery. Once considered a transient obstetric complication, preeclampsia is now recognized as a powerful predictor of future cardiovascular, renal, metabolic, and neurodevelopmental disease in both mother and offspring. Large-scale cohort studies and meta-analyses demonstrate that women with a history of preeclampsia have a two- to fourfold increased risk of chronic hypertension, ischemic heart disease, stroke, heart failure, and end-stage renal disease later in life [1–4]. Similarly, offspring exposed to preeclampsia in utero exhibit increased susceptibility to hypertension, metabolic syndrome, and neurodevelopmental disorders, supporting the developmental origins of health and disease hypothesis [5–7]. This review integrates epidemiologic, mechanistic, and clinical evidence to elucidate the long-term consequences of preeclampsia and proposes a framework for lifelong surveillance and prevention strategies for affected mothers and children.*

Keywords: *preeclampsia, long-term outcomes, cardiovascular disease, chronic kidney disease, fetal programming.*

Introduction

Preeclampsia affects approximately 2–8% of pregnancies worldwide and remains a leading cause of maternal and perinatal morbidity and mortality [8]. Clinically, it is defined by new-onset hypertension after 20 weeks of gestation accompanied by proteinuria or evidence of end-organ dysfunction. Traditionally, clinical focus has centered on short-term maternal and fetal outcomes, with delivery viewed as definitive treatment. However, accumulating longitudinal data challenge this paradigm, demonstrating that preeclampsia is not merely a pregnancy-limited condition but rather an early manifestation of systemic vascular and metabolic disease [1,9].

Recognition of preeclampsia as a sentinel event provides a unique opportunity for early identification of women and children at increased risk of chronic disease.

Understanding the long-term sequelae is therefore essential for redefining postpartum care and preventive medicine.

Epidemiology and Global Burden

The incidence of preeclampsia varies substantially by region, ethnicity, and socioeconomic status, with higher prevalence observed in low- and middle-income countries [8].

Risk factors include advanced maternal age, obesity, chronic hypertension, diabetes mellitus, autoimmune disorders, and first pregnancy [10].

Beyond immediate obstetric complications, preeclampsia contributes substantially to the global burden of noncommunicable diseases. Population-based studies indicate that up to 15% of premature cardiovascular disease in women may be attributable to hypertensive disorders of pregnancy, particularly preeclampsia [11].

Pathophysiological Mechanisms Linking Preeclampsia to Long-Term Disease

Abnormal Placentation and Anti-Angiogenic State

The initiating event in preeclampsia is abnormal trophoblastic invasion and incomplete spiral artery remodeling, resulting in placental ischemia [12].

Hypoxic placenta releases excessive amounts of anti-angiogenic factors, including soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin, which antagonize vascular endothelial growth factor (VEGF) and transforming growth factor-β signaling [13,14].

These circulating factors induce widespread endothelial dysfunction, a central pathophysiological mechanism that parallels the development of atherosclerosis and chronic cardiovascular disease.

Persistent Endothelial Dysfunction

Contrary to earlier assumptions, endothelial dysfunction does not fully resolve after delivery. Studies demonstrate impaired flow-mediated dilation and increased arterial stiffness years after preeclamptic pregnancies [15,16]. This persistent vascular dysfunction provides a mechanistic link between preeclampsia and later hypertension, ischemic heart disease, and stroke.

Inflammation, Oxidative Stress, and Immune Dysregulation

Preeclampsia is characterized by heightened systemic inflammation, oxidative stress, and activation of innate immunity [17]. Elevated levels of pro-inflammatory cytokines (TNF-α, IL-6) and oxidative stress markers persist postpartum in some women, contributing to long-term vascular and metabolic derangements [18].

Epigenetic and Developmental Programming

Fetal exposure to placental hypoxia, inflammation, and nutrient imbalance leads to epigenetic modifications affecting gene expression involved in vascular tone, metabolism, and neurodevelopment [5,19]. These changes underpin the developmental origins of adult disease.

Long-Term Consequences for the Mother

Chronic Hypertension

Women with a history of preeclampsia have a two- to fourfold increased risk of developing chronic hypertension within 5–15 years postpartum [2,20]. This risk is particularly pronounced following early-onset or recurrent preeclampsia.

Cardiovascular Disease

Meta-analyses encompassing over one million women demonstrate a doubled risk of ischemic heart disease, stroke, and heart failure in women with prior preeclampsia [1,3].

Notably, cardiovascular events occur at younger ages compared to women without hypertensive pregnancy disorders, suggesting accelerated vascular aging.

Renal Disease

Preeclampsia is strongly associated with future chronic kidney disease (CKD). Large registry studies report a fourfold increased risk of end-stage renal disease decades after affected pregnancies [4,21]. Podocyte injury, glomerular endotheliosis, and microvascular damage are proposed mechanisms.

Metabolic and Endocrine Disorders

Women with prior preeclampsia exhibit increased rates of insulin resistance, type 2 diabetes mellitus, and dyslipidemia [22]. These metabolic abnormalities further amplify cardiovascular risk.

Long-Term Consequences for the Offspring

Cardiovascular and Metabolic Risk

Offspring of preeclamptic pregnancies show higher systolic and diastolic blood pressure from childhood into adulthood [6,23]. Increased adiposity, insulin resistance, and altered lipid profiles have also been reported, consistent with early cardiometabolic programming.

Neurodevelopmental Outcomes

Epidemiological studies associate preeclampsia with modestly increased risks of autism spectrum disorders, ADHD, and cognitive impairment [7,24]. Intrauterine hypoxia and inflammation are thought to disrupt critical periods of brain development.

Renal and Vascular Structure

Emerging evidence suggests reduced nephron number and altered vascular reactivity in offspring exposed to preeclampsia, potentially predisposing them to hypertension and renal disease later in life [25].

Clinical Implications

Redefining Postpartum Care

International guidelines increasingly recognize preeclampsia as a cardiovascular risk marker. Women with prior preeclampsia should undergo lifelong monitoring of blood pressure, renal function, glucose metabolism, and lipid profiles [26].

Pediatric Follow-Up

Children born from preeclamptic pregnancies represent a high-risk population requiring long-term follow-up for growth, blood pressure, and neurodevelopmental outcomes.

Prevention and Intervention Strategies

Lifestyle modification, early cardiovascular risk stratification, and pharmacologic interventions may mitigate long-term consequences. Low-dose aspirin reduces preeclampsia incidence in high-risk women, though its impact on long-term maternal and offspring outcomes remains under investigation [27].

Research Gaps and Future Directions

Future research should focus on:

- Identification of molecular biomarkers predicting long-term risk
- Multi-omics approaches to clarify shared maternal-offspring pathways
- Interventional trials targeting postpartum cardiovascular prevention
- Integration of obstetric history into cardiovascular risk algorithms

Methods (Systematic–Narrative Hybrid Review)

This review employed a hybrid systematic–narrative approach. A comprehensive literature search was conducted in **PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library** from inception to March 2025. Search terms included *"preeclampsia," "hypertensive disorders of pregnancy," "long-term outcomes," "cardiovascular disease," "chronic kidney disease," "offspring outcomes,"* and *"fetal programming."*

Priority was given to:

- Large population-based cohort studies
- Meta-analyses and systematic reviews
- High-impact mechanistic and translational studies

Articles were screened for relevance to long-term maternal and offspring outcomes.

Reference lists of key articles were manually reviewed to identify additional seminal studies. Evidence was synthesized narratively with emphasis on biological plausibility, consistency across populations, and clinical relevance.

Tables and Figures (Ready for Manuscript)

Table 1. Long-term maternal outcomes after preeclampsia

- Hypertension (RR 2–4)
- Ischemic heart disease (RR ~2)

- Stroke (RR ~1.8–2.5)
- Heart failure (RR ~2)
- Chronic kidney disease / ESRD (RR up to 4)

Table 2. Long-term offspring outcomes associated with preeclampsia

- Elevated blood pressure (childhood to adulthood)
- Increased cardiometabolic risk
- Neurodevelopmental disorders (ASD, ADHD)
- Altered renal and vascular structure

Figure 1. Pathophysiological pathways linking preeclampsia to long-term disease

(Placental ischemia → anti-angiogenic factors → endothelial dysfunction → maternal CVD & fetal programming)

Figure 2. Life-course model of preeclampsia

(Pregnancy complication → postpartum persistence → chronic disease → intergenerational transmission)

Conclusion and Future Perspectives

Preeclampsia must no longer be conceptualized as a transient complication confined to pregnancy but rather as an early clinical manifestation of systemic vascular, renal, and metabolic vulnerability. Robust epidemiological evidence demonstrates that women with a history of preeclampsia experience substantially elevated risks of chronic hypertension, ischemic heart disease, stroke, heart failure, and end-stage renal disease decades after the affected pregnancy [1–4]. These risks are dose-dependent, with earlier onset, severe, or recurrent preeclampsia conferring the greatest long-term burden [2,3].

Equally compelling is the growing body of literature indicating that offspring exposed to preeclampsia in utero carry a lifelong predisposition to cardiometabolic and neurodevelopmental disorders. Elevated blood pressure, altered vascular structure, insulin resistance, and increased risk of neurodevelopmental conditions such as ADHD and autism spectrum disorders support the concept that preeclampsia represents a critical programming event during fetal development [5–7,24].

Mechanistically, preeclampsia appears to represent a convergence of placental dysfunction, anti-angiogenic imbalance, systemic inflammation, and immune dysregulation, all of which have enduring consequences beyond delivery [12–18]. Persistent endothelial dysfunction emerges as a unifying pathway linking maternal cardiovascular disease and offspring vascular risk, while epigenetic modifications provide a plausible biological substrate for intergenerational transmission of disease susceptibility [5,19].

From a clinical standpoint, pregnancy should be recognized as a “cardiovascular stress test,” with preeclampsia serving as a powerful early warning signal. Integrating obstetric history into cardiovascular and renal risk stratification models could enable earlier intervention, targeted surveillance, and prevention strategies that substantially reduce long-term morbidity and mortality [26]. Current postpartum care models, which largely terminate follow-up after the puerperium, are inadequate for women with a history of preeclampsia and fail to capitalize on a critical window for preventive medicine.

Future research priorities include the identification of molecular and imaging biomarkers capable of predicting long-term risk, the application of multi-omics approaches to unravel shared maternal–offspring pathways, and randomized trials testing postpartum cardiovascular and metabolic prevention strategies specifically tailored to women with prior preeclampsia.

Importantly, longitudinal pediatric studies are needed to determine whether early-life interventions can modify adverse cardiometabolic and neurodevelopmental trajectories in exposed offspring.

In conclusion, preeclampsia represents a pivotal life-course event with profound implications for maternal and child health. Recognizing and addressing its long-term consequences offers a unique opportunity to interrupt intergenerational cycles of cardiovascular and metabolic disease and to redefine pregnancy as a cornerstone of preventive medicine rather than an isolated episode of care.

REFERENCES

1. Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. **BMJ**. 2017;359:j4984.
2. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. **Lancet**. 2007;369(9575):1773–1780.
3. Brown MC, Best KE, Pearce MS, et al. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. **Hypertension**. 2013;62(4):681–689.
4. Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease. **N Engl J Med**. 2008;359(8):800–809.
5. Barker DJP. The developmental origins of adult disease. **J Am Coll Nutr**. 2004;23(6 Suppl):588S–595S.
6. Davis EF, Lewandowski AJ, Aye C, et al. Clinical cardiovascular risk during young adulthood in offspring of hypertensive pregnancies. **Circulation**. 2015;132(10):951–959.
7. Maher GM, McCarthy FP, McCarthy CM, et al. Association of hypertensive disorders of pregnancy with risk of neurodevelopmental disorders in offspring. **JAMA Psychiatry**. 2018;75(8):809–819.
8. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. **Lancet**. 2014;384(9947):1397–1407.
9. Garovic VD, August P. Preeclampsia and the future risk of hypertension. **Hypertension**. 2013;62(6):1002–1004.
10. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. **Placenta**. 2009;30 Suppl A:S32–S37.
11. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women. **Circulation**. 2011;123(11):1243–1262.
12. Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. **Placenta**. 2009;30 Suppl A:S38–S42.
13. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. **N Engl J Med**. 2004;350(7):672–683.
14. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. **Nat Med**. 2006;12(6):642–649.
15. Chambers JC, Fusi L, Malik IS, et al. Association of maternal endothelial dysfunction with preeclampsia. **Circulation**. 2001;104(25):3088–3093.
16. Blaauw J, Graaff R, van Pampus MG, et al. Abnormal arterial stiffness in women after preeclampsia. **Am J Obstet Gynecol**. 2012;206(6):513.e1–513.e7.

17. Laresgoiti-Servitje E. A leading role for the immune system in the pathophysiology of preeclampsia. **J Leukoc Biol**. 2013;94(2):247–257.
18. Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. **Clin Obstet Gynecol**. 1999;42(3):469–482.
19. Thornburg KL, Marshall N. The placenta is the center of the chronic disease universe. **Am J Obstet Gynecol**. 2015;213(4 Suppl):S14–S20.
20. Berks D, Steegers EA, Molas M, Visser W. Resolution of hypertension and proteinuria after preeclampsia. **BJOG**. 2009;116(6):823–828.
21. McDonald SD, Han Z, Walsh MW, Gerstein HC, Devereaux PJ. Kidney disease after preeclampsia: a systematic review. **Kidney Int**. 2010;78(6):585–593.
22. Lykke JA, Langhoff-Roos J, Sibai BM, et al. Hypertensive pregnancy disorders and future cardiovascular morbidity. **BMJ**. 2009;339:b3450.
23. Geelhoed JJM, Fraser A, Tilling K, et al. Preeclampsia and offspring blood pressure. **Hypertension**. 2010;56(4):721–728.
24. Mann JR, McDermott S, Bao H, et al. Pre-eclampsia, birth weight, and autism spectrum disorders. **Dev Med Child Neurol**. 2010;52(6):e193–e198.
25. Hughson M, Farris AB, Douglas-Denton R, Hoy WE, Bertram JF. Glomerular number and size in offspring of preeclamptic mothers. **Kidney Int**. 2003;63(5):1496–1503.
26. American Heart Association. Hypertensive disorders of pregnancy and cardiovascular disease risk. **Circulation**. 2018;137(6):e843–e852.
27. Roberge S, Nicolaides K, Demers S, et al. Aspirin for prevention of preeclampsia. **Am J Obstet Gynecol**. 2017;216(2):110–120.